News & Updates

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.

Ethnic differences emerge in stroke patterns within Singapore, with a study finding showing that Indians have lower rates of haemorrhagic stroke and a lower proportion of female patients compared with the Chinese and Malay populations.

Patients with cirrhosis and nonvalvular atrial fibrillation (AF) who initiated rivaroxaban are more likely to experience major haemorrhage than those administered with apixaban, according to a study. However, the rates of ischaemic events and death are similar between the two treatment groups.

New drug applications approved by US FDA as of 1-15 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A 10-week study presented at EAN 2024 has shown that a ketogenic or “keto” diet plus regular physical exercise may be beneficial for people with narcolepsy.

The use of the alpha-1 adrenergic receptor antagonists (alpha-blockers) terazosin, doxazosin, and alfuzosin—medications for benign prostate hyperplasia (BPH)—may help reduce the incidence of dementia with Lewy bodies (DLB) in men, as suggested in a study.